Senores Pharmaceuticals
- Market cap
- ₹ 5,600 Cr.
- P/E
- 48.3x
- P/B
- 5.93x
- 52-week range
- 706 – 1,599
- ROE
- 13%
- ROCE
- 15%
- Dividend yield
- 0%
- Debt / equity
- 0.37
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Senores Pharmaceuticals Limited is an India-based company. The Company is engaged in the development and manufacturing of a pharmaceutical product. The Company manufactures products of international quality to cater to the increasing new age demands of the global healthcare industry. The Company's products include Acetaminophen + Butalbital Tablet, Candesartan Cilexetil + HCTZ Tablet, Losartan Potassium Tablet, Chlorzoxazone Tablet, Clomiphene Tablet, Deferiprone Tablet, Diltiazem ER Capsule, Enalapril Maleate Tablet, Escitalopram Tablet, Irbesartan Tablet, Olmesartan Medoxomil Tablet and others. It supplies affordable Active Pharmaceutical Ingredients (API) to generic formulations manufacturers. Its product API includes Anastrozole, Aripiprazole, Benfotiamine, Clomiphene Citrate, Desloratadine, Desvenlafaxine Succinate, Fluoxetine Hydrochloride, and others. Its domestic portfolio includes Immunosen - Human Normal Immunoglobulin, Senumin - Human Normal Albumin and others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Senores Pharmaceuticals against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)48.3 against a typical 34.3: pricier than most peers (1st = cheapest).152nd of 220
- Sales growth+30.4% against a typical +15.6% from a year earlier.57th of 197
- Profit growth+42.9% against a typical +18.9% from a year earlier.58th of 160
- Share price, 3 months+0.2% against a typical −0.5%.96th of 200
- Size₹ 5,600.1 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).53rd of 199
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 29 Oct 2026Upcoming | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 27 Jul 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters |
| 14 May 2026 | Financial Results/Other business matters | To consider and approve Audited Consolidated and Standalone Financial Results Of The Company For The Quarter And financial year Ended March 31, 2026 And To Transact Other Business Matters |
| 20 Jan 2026 | Financial Results/Other business matters | Senores Pharmaceuticals Limited has informed the exchange that the meeting of the Board of Directors of the Company is scheduled on January 20, 2026 ,inter alia, to consider and approve Un-audited Standalone and Consolidated Financial Results of the Company for the quarter and Nine Months ended December 31, 2025 and to transact other business matters |
| 7 Jan 2026 | Fund Raising/Other business matters | Senores Pharmaceuticals Ltd has informed the exchange that the meeting of the Board of Directors of the Company is scheduled on 07/01/2026, inter alia, to consider and approveproposals for raising funds by way of issue of convertible warrants on preferential basis to the promotors/promoter group including determination of issue price. |
| 6 Nov 2025 | Financial Results/Other business matters | To consider and approve the financial results for the quarter and half year ended September 30, 2025 and to transact other business matters |
| 23 Jul 2025 | Financial Results/Other business matters | Senores Pharmaceuticals Limited has informed the Exchange about Board Meeting to be held on July 23, 2025 to consider and approve the Un-audited Standalone and Consolidated financial results of the Company for the quarter ended June 30, 2025 and to transact other business matters. |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 79 | 102 | 80 | 101 | 103 | 114 | 138 | 162 | 171 | 175 | 180 |
| Expenses | 64 | 80 | 59 | 77 | 77 | 95 | 104 | 112 | 121 | 128 | 126 |
| Operating Profit | 15 | 22 | 21 | 23 | 26 | 19 | 34 | 50 | 50 | 47 | 54 |
| OPM % | 19% | 22% | 27% | 23% | 25% | 17% | 25% | 31% | 29% | 27% | 30% |
| Other Income | 1 | 2 | 0 | 2 | 5 | 12 | 3 | 5 | 7 | 18 | 3 |
| Interest | 2 | 3 | 5 | 5 | 6 | 5 | 5 | 6 | 5 | 8 | 7 |
| Depreciation | 3 | 4 | 4 | 4 | 4 | 5 | 6 | 8 | 8 | 9 | 10 |
| Profit before tax | 10 | 18 | 13 | 16 | 20 | 21 | 26 | 41 | 45 | 47 | 39 |
| Tax % | 31% | 19% | 19% | 18% | 20% | 13% | 20% | 26% | 25% | 23% | 23% |
| Net Profit | 7 | 14 | 11 | 13 | 16 | 18 | 21 | 30 | 34 | 37 | 30 |
| EPS in Rs | 2.37 | 5.23 | 3.23 | 3.86 | 3.73 | 3.87 | 4.28 | 7.03 | 6.87 | 6.86 | 6.67 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 162%
- TTM
- 51%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 139%
- TTM
- 87%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- 14%
- 3 Years
- 14%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Senores Pharmaceuticals | ₹ 1,320.40 | ₹ 5,600 Cr. | 48.3x | 5.9x | 13% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Deval Rajnikant Shah
- Chief Financial Officer, Whole Time Director
- Chetan Bipinchandra Shah
- Chief Operating Officer, Whole Time Director
- Swapnil Jatinbhai Shah
- Managing Director, Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.